2. MPW)
(Revised as per Technical Operational Guideline for
TB Control-2016 & Revised PMDT Guideline-2017)
(Revised: March 2018)
3. RNTCP
RNTCP PMDT
Intensified TB Case Finding)
Annexure I : MPW
Annexure II :
AnnexureIII :
Revised Annexure 15 A Form 11-12
I&II-এর ২৩
Daily Regimens, FDC & Weight Bands 24
Integrated DR-TB algorithm & follow-up protocol 25A & 25B
Patient councelling & community involvement 49A
99DOTs & DBT scheme 51A
RNTCP structure & Key personnels 59
Role play 60-61
4. Some of the common abbreviations used in RNTCP
ACF/ICF Active case findings/intensified case findings
ADR Adverse drug reaction
AE Adverse event
AFB Acid Fast bacilli
AIC Airborne infection control
AIDS Acquired Immune Deficiency Syndrome
ALT Alanine aminotransferase
Am Amikacin
Amx/Clv Amoxicillin/clavulanate
ART Anti-retroviral therapy
AST Aspartate aminotransferase
ATS American Thoracic Society
Bdq Bedaquiline
BPL Below poverty line
CAP Conditional Access Programme
CBNAAT Cartridge Based Nucleic Acid Amplification Test
CEM Cohort event monitoring
Cfz Clofazimine
Clr Clarithromycin
Cm Capreomycin
CMO Chief Medical Officer
CP Continuation phase
CPT Co-trimoxazole preventive therapy
Cs Cycloserine
CTD Central TB Division
CUP Compassionate Use Programme
C-DAC Centre for Development of Advanced Computing
C-DST Culture and Drug Susceptibility Test
CL-HIV Children living with HIV
DAIDS Division of AIDS
DBT Direct Beneficiary Transfer
DCGI Drugs Controller General of India
DDG Deputy Director General
DDS District drug store
DDR-TBC District DR-TB Centre
DG Director General
DGHS Directorate General of Health Services
Dlm Delamanid
DMC Designated microscopy centre
DOT Directly observed treatment
DRT Drug resistance testing
DR-TB Drug-resistant tuberculosis
DR-TBC Drug-Resistant Tuberculosis Centre
DSMC Drug Safety Monitoring Committee
5. DST Drug susceptibility testing
DTO District TB officer
DVDMS Drug & vaccine distribution management system
E Ethambutol
ECG Electrocardiogram
ECHO Extension of Community Health Care Outcomes
EP-TB Extra-pulmonary tuberculosis
EQA External quality assurance
Eto Ethionamide
EU European Union
FDA Food and Drug Administration
FEFO First expiry first out
FL-LPA First line-line probe assay
FO Field Officer
FQ Fluoroquinolone
GLC Green Light Committee
GFATM Global Fund for AIDS, Tuberculosis & Malaria
Gfx Gatifloxacin
GMSD General Medical Stores Depot
GoI Government of India
H Isoniazid
Hh High dose isoniazid
HRCT High resolution CT scan
ICH International Conference on Harmonization
ICT Information communication technology
ICMR Indian Council for Medical Research
IP Intensive phase
Ipm Imipenem
IPAQT Initiative for promoting affordable & quality TB test
IQC Internal Quality Control
IRL Intermediate reference laboratory
ISO International Standard Organization
Km Kanamycin
LC Liquid culture
LFT Liver function test
Lfx Levofloxacin
L J Lowenstein Jensen
LPA Line probe assay
LT Laboratory technician
LTFU Lost to follow up
Lzd Linezolid
MAC Mycobacterium avium complex
MDR-TB Multidrug-resistant TB
Mfx Moxifloxacin
Mfxh High dose Moxifloxacin
6. MGIT Mycobacteria growth indicator tube
MIS Management information system
MO Medical Officer
MoHFW Ministry of Health and Family Welfare
MO-DMC Medical Officer-designated microscopy centre
MO-PHI Medical Officer- peripheral health institute
MO-TC Medical Officer TB control
MOTT Mycobacterium other than tubercle bacilli
MoU Memorandum of understanding
Mpm Meropenem
MPR Mixed pattern resistance
MR Mono resistance
MSS Monthly stock statement
NAAT Nucleic Acid Amplification Test
NABL National accreditation board for laboratories
NDRS National Drug Resistance Survey
NDR-TBC Nodal DR-TB Centre
NGO Non-Government Organization
NGS Next-Generation Sequencing
NHPS National health protection scheme
NHM National Health Mission
NIRT National Institute for Research in Tuberculosis
NITRD National Institute for Tuberculosis and Respiratory Diseases
NRL National reference laboratory
NSP National strategic plan
NTI National TB institute
NTM Non-Tuberculous Mycobacterium
OBR Optimized background regimen
Ofx Ofloxacin
OPD Out Patient Department
PAS p-aminosalicylic acid
Pdx Pyridoxine
PDR Poly drug resistance
PHI Peripheral health institute
PK/PD Pharmacokinetic/pharmacodynamics
PL-HIV People living with HIV
PMDT Programmatic management of drug-resistant tuberculosis
PP Private Provider
PQC Product quality compliance
PSM Procurement and supply management
PT Previously treated
PTE Pre-treatment evaluation
Pto Protionamide
PvPI Pharmaco-vigilance programme of India
QA Quality assurance
7. QSE Quality System Elements
R Rifampicin
RNTCP Revised National Tuberculosis Control Programme
RR-TB Rifampicin-resistant tuberculosis
R&R Recording & reporting
RT-MERM Real time medication event reminder monitor device
S Streptomycin
SA Statistical Assistant
SAE Serious adverse event
SDG Sustainable Development Goals
SDS State drug store
SLD Second line anti-TB drugs
SLDST Second line drug susceptibility testing
SLI Second line injectable
SL-LPA Second line-line probe assay
SME Supervision, Monitoring & Evaluation
SoP Standard operating procedures
SPC Specimen Processing Control
STLS Senior TB Laboratory Supervisor
STO State TB Officer
STR Standardized treatment regimen
STS Senior treatment supervisor
TALFU Treatment after lost to follow up
TA Touch Agent
TAT Turn-around time
TB Tuberculosis
TBHV TB Health Visitor
THALI TB Health Action Learning Initiative
Thz Thioacetazone
ToR Terms of reference
Trd Terizidone
TU TB Unit
UDST Universal Drug Susceptibility Testing
ULN Upper limit of normal
UPT Urine pregnancy test
USAID United States Agency for International Development
USFDA United States Food & Drug Administration
WCO World Health Organization Country Office for India
WHO World Health Organization
WHP World Health Partners
XDR-TB Extensively-drug resistant TB
Z Pyrazinamide
29. 21
PHI
CAT II
Prolongation IP)
Cat I m¡m 24 12 18 54
Cat II e£m 36 12 22 66
Prolongation Pouch
Anti TB Regimen- First Line -Standard Tri Weekly regimen for Drug sensitive TB
ea¥e LÉ¡V¡N¢l I 1.ea¥e Øf¥V¡j Øj£u¡l f¢S¢Vi
2.
3.
2HRZE + 4HR
II
1.
f¢S¢Vi
2.
3.
f¢S¢Vi
4. AeÉeÉ
2H R Z E S+1 H R Z E+5 H R E
Intermittent)
¡N£
¡CX, ¢lg¡j¢f¢pe, f¡ul¡¢Se¡j¡CX, Cb¡j¢hEVm
40. 28
l (Treatment Supporter)
(Annexure 15C)
PHI/CHC
e¡j, hup, APL, BPL,
ll
l
l
-
- ¢Q¢Lvp¡l gm¡gm pC J a¡¢lM ;
- LaSe hÉ¢š² I
INH
-
( Record Remarks)
LÉ¡V I J LÉ¡V II , fË¢a¢ce h¡ p¢hl¡j ü¡ÙÛÉ¢h¢d( Daily or Intermittent Regimen)z
(Record drug administration in intensive phase)
-
o ¢Qq²¢V ¢cez
41. 29
-
p¤¤¢hd¡Se s
I II
I V¡N¢l II
CDST (CBNAAT/LPA)
(Record drug administration and collection in
continuation phase)
p¡jh¡l h¤dh¡l J öœ²h¡l
z Hhw ×
× ×---------------z
- supervised unsupervised O- not taken.
: ( Monitor drug collection and recording)
Cat I
April 22nd
dose
O
23rd
dose
24th
dose
S S
April 22nd
dose
O
23rd
dose
S
24th
dose
S
42. 30
April X
17
S O S X
18
p
April X
16
S O X S X
18
(Patient's TB Identity Card) Annexure 15 D
TU ,
PHI
PHI Update)
Nikshay entry Identity Card)